CELYAD ONCOLOGY (CYAD.BR) Fundamental Analysis & Valuation

EBR:CYAD • BE0974260896

Current stock price

0.313 EUR
-0.01 (-2.19%)
Last:

This CYAD.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CYAD.BR Profitability Analysis

1.1 Basic Checks

  • In the past year CYAD was profitable.
  • CYAD had a negative operating cash flow in the past year.
  • In the past 5 years CYAD reported 4 times negative net income.
  • CYAD had a negative operating cash flow in each of the past 5 years.
CYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFCYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of CYAD (19.31%) is better than 90.48% of its industry peers.
  • Looking at the Return On Equity, with a value of 34.07%, CYAD belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
Industry RankSector Rank
ROA 19.31%
ROE 34.07%
ROIC N/A
ROA(3y)-30.41%
ROA(5y)-66.4%
ROE(3y)-413.22%
ROE(5y)-449.73%
ROIC(3y)N/A
ROIC(5y)N/A
CYAD.BR Yearly ROA, ROE, ROICCYAD.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

1.3 Margins

  • CYAD has a better Profit Margin (3952.38%) than 98.81% of its industry peers.
  • With a Gross Margin value of 61.90%, CYAD perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
  • CYAD's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 3952.38%
GM 61.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-9.15%
CYAD.BR Yearly Profit, Operating, Gross MarginsCYAD.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K -400K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CYAD.BR Health Analysis

2.1 Basic Checks

  • CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CYAD has been increased compared to 1 year ago.
  • The number of shares outstanding for CYAD has been increased compared to 5 years ago.
  • CYAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYAD.BR Yearly Shares OutstandingCYAD.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
CYAD.BR Yearly Total Debt VS Total AssetsCYAD.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • CYAD has an Altman-Z score of 1.78. This is a bad value and indicates that CYAD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.78, CYAD is in line with its industry, outperforming 48.81% of the companies in the same industry.
  • There is no outstanding debt for CYAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.78
ROIC/WACCN/A
WACC7.81%
CYAD.BR Yearly LT Debt VS Equity VS FCFCYAD.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • CYAD has a Current Ratio of 1.92. This is a normal value and indicates that CYAD is financially healthy and should not expect problems in meeting its short term obligations.
  • CYAD has a Current ratio of 1.92. This is in the lower half of the industry: CYAD underperforms 60.71% of its industry peers.
  • CYAD has a Quick Ratio of 1.92. This is a normal value and indicates that CYAD is financially healthy and should not expect problems in meeting its short term obligations.
  • CYAD has a Quick ratio of 1.92. This is comparable to the rest of the industry: CYAD outperforms 44.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
CYAD.BR Yearly Current Assets VS Current LiabilitesCYAD.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CYAD.BR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 109.53% over the past year.
  • Looking at the last year, CYAD shows a very negative growth in Revenue. The Revenue has decreased by -88.71% in the last year.
  • CYAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.24% yearly.
EPS 1Y (TTM)109.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%252.16%
Revenue 1Y (TTM)-88.71%
Revenue growth 3YN/A
Revenue growth 5Y33.24%
Sales Q2Q%-95.93%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2024 2025 2M 4M 6M 8M
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. CYAD.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 31.30 indicates a quite expensive valuation of CYAD.
  • CYAD's Price/Earnings ratio is a bit cheaper when compared to the industry. CYAD is cheaper than 73.81% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.53. CYAD is around the same levels.
Industry RankSector Rank
PE 31.3
Fwd PE N/A
CYAD.BR Price Earnings VS Forward Price EarningsCYAD.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD.BR Per share dataCYAD.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYAD.BR Dividend Analysis

5.1 Amount

  • CYAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYAD.BR Fundamentals: All Metrics, Ratios and Statistics

CELYAD ONCOLOGY

EBR:CYAD (4/16/2026, 11:18:34 AM)

0.313

-0.01 (-2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-02
Earnings (Next)N/A
Inst Owners58.59%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap14.01M
Revenue(TTM)21.00K
Net Income(TTM)830.00K
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 31.3
Fwd PE N/A
P/S 667.14
P/FCF N/A
P/OCF N/A
P/B 5.75
P/tB 5.79
EV/EBITDA N/A
EPS(TTM)0.01
EY3.19%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.110659 (-64.65%)
Profitability
Industry RankSector Rank
ROA 19.31%
ROE 34.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3952.38%
GM 61.9%
FCFM N/A
ROA(3y)-30.41%
ROA(5y)-66.4%
ROE(3y)-413.22%
ROE(5y)-449.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-9.15%
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z 1.78
F-Score3
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)47.95%
Cap/Depr(5y)35.65%
Cap/Sales(3y)326.38%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%252.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-88.71%
Revenue growth 3YN/A
Revenue growth 5Y33.24%
Sales Q2Q%-95.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y75.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.48%
OCF growth 3YN/A
OCF growth 5YN/A

CELYAD ONCOLOGY / CYAD.BR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CELYAD ONCOLOGY (CYAD.BR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYAD.BR.


What is the valuation status for CYAD stock?

ChartMill assigns a valuation rating of 1 / 10 to CELYAD ONCOLOGY (CYAD.BR). This can be considered as Overvalued.


How profitable is CELYAD ONCOLOGY (CYAD.BR) stock?

CELYAD ONCOLOGY (CYAD.BR) has a profitability rating of 3 / 10.


What is the financial health of CELYAD ONCOLOGY (CYAD.BR) stock?

The financial health rating of CELYAD ONCOLOGY (CYAD.BR) is 5 / 10.